Clinical Trials

490 enrolled 33 charts

Small Cell Lung Carcinoma

NCT04302025 2026-04-03

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Phase 2 Recruiting

99 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05047250 2026-04-03

A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06179069 2026-04-03

A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Phase 1 Recruiting

339 enrolled

SCLC

NCT06646276 2026-04-03

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Phase 3 Recruiting

530 enrolled

Phase 3 Not yet recruiting

Small Cell Lung Carcinoma

NCT07472517 2026-03-31

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

670 enrolled

Small Cell Lung Carcinoma

NCT07284121 2026-03-27

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Recruiting

700 enrolled

GastrointestinalThoracic

Carcinoma, Hepatocellular, Lung Neoplasms

NCT04432207 2026-03-25

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Phase 1 Terminated

24 enrolled

Phase 1/2 Active not recruiting

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT05142696 2026-03-17

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

24 enrolled

Extensive Stage Small Cell Lung Cancer

NCT04832854 2026-03-11

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Phase 2 Terminated

50 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT05091567 2026-03-10

IMforte

660 enrolled 23 charts 3 FDA

Phase 2/3 Active not recruiting

Small Cell Lung Carcinoma

NCT03178552 2026-03-09

B-FAST

1,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

184 enrolled

Phase 1/2 Active not recruiting

Bites and Stings, Lung Neoplasms

NCT04471727 2026-02-24

MK-6070-001

232 enrolled

EndocrineGenitourinaryNETThoracic

Lung Neoplasms, Prostatic Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT04665856 2026-02-13

SKYSCRAPER-02C

123 enrolled 26 charts

Small Cell Lung Carcinoma

NCT06712355 2026-02-13

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Phase 3 Recruiting

621 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04449874 2026-02-12

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

498 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT06362252 2026-02-06

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Phase 1/2 Recruiting

123 enrolled

Extensive Stage-small Cell Lung Cancer

NCT02486718 2026-02-05

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

1,280 enrolled 24 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT06898957 2026-02-05

(DeLLphi-310)

Phase 1 Recruiting

200 enrolled

Small Cell Lung Carcinoma

NCT04619797 2026-02-03

SKYSCRAPER-06

Phase 2/3 Completed

542 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06267001 2026-02-03

SKYSCRAPER-15

56 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05867121 2026-02-02

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

GastrointestinalGenitourinaryThoracic

102 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Stomach Neoplasms

NCT04294810 2026-01-30

SKYSCRAPER-01

620 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03456063 2026-01-22

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

453 enrolled

Non-Small-Cell Lung

NCT03563716 2026-01-20

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

135 enrolled 12 charts

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

40 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03782207 2026-01-08

IMreal

Active not recruiting

2,756 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Small Cell Lung Carcinoma

NCT04471428 2025-12-22

CONTACT-01

366 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT03337698 2025-12-12

Morpheus Lung

Phase 1/2 Completed

314 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05171777 2025-12-11

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Phase 2 Completed

179 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung

NCT03735121 2025-12-05

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

438 enrolled 40 charts 3 FDA

DermatologicGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung

NCT06332755 2025-11-24

LB-LR1109

Phase 1 Recruiting

76 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma

NCT05468489 2025-10-21

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

200 enrolled

Extensive Stage Small Cell Lung Cancer

NCT05703971 2025-10-16

Acclaim-3

Phase 1/2 Recruiting

62 enrolled

Small Cell Lung Cancer Extensive Stage

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

142 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT03041311 2025-09-25

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Phase 2 Completed

107 enrolled 42 charts

Small Cell Lung Carcinoma

NCT05652686 2025-09-23

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Phase 1/2 Recruiting

203 enrolled

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT04513925 2025-09-08

SKYSCRAPER-03

829 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03170960 2025-08-17

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors